Effects of Testosterone in Women With Depression: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Effects of Testosterone in Women With Depression (NCT00676676), a na na study. The primary outcome is Montgomery-Asberg Depression Rating Scale (MADRS) Scale.

2. Clinical Question

The study description frames the question around women whose depression persisted despite antidepressant treatment, including SSRI- or SNRI-resistant depression. It notes that testosterone administration in women with this treatment-resistant depression had not been studied in the context described. The trial was designated a pilot study, and enrollment was 9. This small single-group study can describe how scores changed among its participants if those measurements are reported, but it does not include a concurrent untreated or alternative-treatment group for comparison.

The clinical question is therefore exploratory: it concerns the course of MADRS scores during the period of testosterone use alongside current antidepressant therapy. The record does not report whether antidepressant regimens were standardized, whether treatment adherence was assessed, or what specific change was designated as clinically meaningful. Those details would be needed to interpret the measurement and its relevance beyond the study participants.

3. Trial Design

This was a completed pilot study with enrollment of 9. The record lists the study start as 2007-03 and primary completion as 2008-10. The study phase is listed as NA. Massachusetts General Hospital is listed as the sponsor.

The design is recorded as single-group, with allocation listed as NA and masking listed as NONE. The registry record describes one intervention: a testosterone patch delivering 300mcg daily for 8-weeks. The study description says testosterone was to be added to current antidepressant therapy for women who remained depressed despite adequate antidepressant doses. No separate control arm or randomized treatment assignment is described. Consequently, the design does not support a direct comparison of testosterone against placebo or another intervention.

The primary measure is MADRS, recorded as a mean with standard deviation. Its timeframe is baseline, 2-week, and 8-week. The registry record lists one outcome measure and two analyses, but the specific analyses, the participants included in each, and the statistical procedures are not reported in the registry record. The numerical findings for the primary measure are also not reported in the registry record.

Several design details that could affect interpretation are not reported in the registry record, including eligibility criteria beyond the summary description, the duration and stability of prior antidepressant treatment, the precise visit schedule, adherence procedures, and handling of treatment changes. A protocol or statistical analysis plan is not described in the record. The status is recorded as completed, but that status alone does not establish how many participants completed every assessment or whether all planned measurements were collected.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: This was a pilot protocol

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Montgomery-Asberg Depression Rating Scale (MADRS) Scale, measured over Baseline, 2-week, 8-week.

The primary endpoint is the Montgomery-Asberg Depression Rating Scale (MADRS), a diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. The recorded scale values run from 0 to 60, with higher scores indicating more severe symptoms. In this trial, the registry lists MADRS measurements at baseline, 2-week, and 8-week timepoints.

A repeated measure such as MADRS can describe symptom severity at different stages of a study. Baseline provides a reference measurement, while later assessments can show the observed course during the intervention period. Reporting a mean gives a measure of the group’s average score; the standard deviation describes how dispersed individual scores are around that mean. These summaries do not show every participant’s trajectory, and an average change can conceal substantial variation among participants.

MADRS is used because it provides a structured way to quantify symptom severity rather than relying only on a broad description of improvement or worsening. The registry record does not report the numerical means, standard deviations, changes from baseline, or any measure of uncertainty for the endpoint. It also does not report a threshold for interpreting a change as clinically meaningful. Thus, the endpoint and its measurement schedule are described, but the magnitude and precision of the observed outcome cannot be assessed from the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The primary outcome is a continuous score, and the record specifies a mean and standard deviation as its summary measures. General statistical context: a mean summarizes the center of a set of numeric observations by averaging them, while a standard deviation describes how much observations vary around that center. These measures answer different questions. The mean describes the group’s average score; the standard deviation describes variability among measured scores. Neither one, on its own, establishes how precisely the mean estimates the group’s underlying average.

Because MADRS was scheduled at baseline, 2-week, and 8-week, the observations are repeated measurements on participants rather than independent measurements from unrelated groups. General statistical context: repeated measurements can be analyzed by comparing follow-up scores with baseline scores, by modeling scores across time, or by using another prespecified approach. These approaches make different assumptions and may produce different estimates. The registry record does not identify which approach was used, what contrast was considered primary, or whether the analyses were adjusted for baseline score.

For an interpretable change estimate, a report would generally identify the timepoint or timepoints being compared, the direction of subtraction, the number of participants contributing data, and an uncertainty measure such as a confidence interval. General statistical context: a confidence interval combines an estimated effect with its sampling uncertainty and helps readers judge whether the estimate is precise or compatible with a range of values. A p-value addresses a different question, concerning how unusual the data would be under a specified statistical null model. Neither type of statistic substitutes for the effect estimate itself. The registry record does not report these outcome statistics for MADRS.

The design is single-group, so there is no between-group treatment contrast. General statistical context: a single-group analysis can describe change in the measured participants, but it cannot use random assignment to balance other causes of change across treatment groups. The observed course may be useful as preliminary information, yet it does not isolate the intervention’s effect. A randomized comparison would address a different question by comparing outcomes across assigned groups; no such comparison is described in this record.

The record lists two analyses but does not state whether these are separate endpoint timepoints, alternative models, or other analyses. It also does not identify the model’s assumptions, any covariate adjustment, or whether the analyses were prespecified. Therefore, the analytic meaning of the count of analyses cannot be determined. General statistical context: where multiple comparisons are considered, the chance of at least one apparently notable finding can increase if each is assessed separately. A prespecified analysis plan and a clear account of any multiplicity adjustment help readers understand how results were selected and interpreted. Neither is described in the registry record.

The sample-size illustrations associated with the posted material are planning calculations, not observed power. Their stated assumptions are a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation, and an effect to detect defined as a stated fraction of the observed effect. Those are hypothetical planning assumptions for a two-arm framework; the registered study itself is single-group. The registry record does not report the numerical illustration outputs, and such planning values should not be mistaken for the number of participants actually enrolled or for evidence that the study had a particular probability of detecting an effect. Sample-size calculations are sensitive to assumed effect size, variability, and design.

General statistical context: over-dispersion describes variability greater than a model expects. When it occurs, standard errors from a model that assumes less variability may be too small, making uncertainty look narrower than it is. The primary outcome is continuous and summarized with a mean and standard deviation; the registry record does not state that an over-dispersion problem was assessed or that a model requiring such an assessment was used. No claim about its presence or absence can therefore be made.

Finally, an analysis depends on which participants and measurements are included. General statistical context: an analysis of everyone as assigned, an analysis limited to participants who completed treatment, and an analysis using all available measurements can answer different questions. Missing observations can also alter the composition of the group contributing to each timepoint. The registry record does not report an analysis population, missing-data method, or the number of participants measured at each assessment. These omissions prevent assessment of whether the reported analysis, if any, reflects all enrolled participants or a subset.

10. Multiplicity, Missing Data and Analysis Populations

The record identifies one outcome measure, MADRS, and lists two analyses. It gives baseline, 2-week, and 8-week as the endpoint timeframe, but does not explain how the analyses relate to these measurements. It is therefore not possible to determine which comparison, if any, was treated as the main inferential test or whether additional comparisons were considered.

General statistical context: when several timepoints or outcomes are tested, the overall chance of finding at least one result that appears statistically notable may increase if each test is interpreted separately. Multiplicity procedures can address that issue, but the appropriate approach depends on the planned questions and analysis. A prespecified primary comparison and clear reporting of all analyses help readers distinguish confirmatory from exploratory findings. Any multiplicity adjustment or prespecified testing sequence is not reported in the registry record.

The registry record does not report the number of participants with MADRS data at each timepoint, the extent of missing outcome data, reasons for missingness, or a method for handling missing measurements. It also does not identify the analysis population. General statistical context: complete-case analysis uses participants with the required measurements, while other approaches may use incomplete records under stated assumptions. These choices can affect estimates, especially if the participants with observed follow-up differ systematically from those without it. No particular missing-data approach can be attributed to this study based on the registry record.

Whether the analyses included all enrolled participants, only those who completed the intervention, or another defined group is not reported in the registry record. The record also does not give enough detail to determine whether the two analyses were adjusted, exploratory, or based on distinct populations. The absence of this information limits reproducibility and makes it difficult to evaluate how robust any outcome finding would be to alternative analysis choices.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent non-serious adverse event terms

For the Testosterone group, 9 participants were at risk for serious adverse events and 0 were affected. The registry record lists no serious adverse-event terms. Deaths are not reported in the registry record.

The record also reports that 9 participants were at risk for other adverse events and 2 were affected. These figures should be read as counts within the recorded group, not as proof that an event was or was not caused by the intervention. The registry information does not describe the specific other adverse events, their severity, timing, duration, or relationship to treatment.

General statistical context: event counts in a small group provide limited information about the frequency of uncommon harms, and a count of zero does not establish that no risk exists. The number of participants at risk is important context for interpreting the count. The record does not report further details on safety monitoring, event collection, or how adverse events were attributed. These figures describe what is recorded, but they do not provide a complete characterization of safety.

12. What the Result Does, and Does Not, Mean

This record describes a pilot study of testosterone added to current antidepressant therapy in women with depression that persisted despite adequate antidepressant doses. It identifies the intervention, the single-group design, and MADRS as the primary outcome, with assessments scheduled at baseline, 2-week, and 8-week. Enrollment was 9. These details establish what the study set out to examine, but the numerical MADRS results are not reported in the registry record.

Accordingly, the record does not show whether average MADRS scores rose, fell, or remained similar, nor does it establish the size or precision of any change. Without those outcome estimates, the study’s observed findings cannot be quantitatively characterized. The registry record also does not provide a numerical fatigue result, despite fatigue being mentioned in the study purpose.

Even if a within-group score change were available, the single-group design would limit causal interpretation. General statistical context: symptoms can change over time for reasons other than the intervention, and a baseline-to-follow-up comparison cannot separate those influences without an appropriate comparator and analysis. This is not a randomized treatment comparison, so it cannot establish how outcomes would have differed under another treatment or no added testosterone.

The record does not report enough detail to assess missing outcome data, participant-level variability, or the analysis decisions behind the two listed analyses. Those omissions further limit evaluation of the strength and reproducibility of any result. The pilot designation signals an exploratory study context, but the record does not state a formal sample-size justification or the intended role of the study in later research.

The appropriate reading is therefore bounded: the registry documents a small, single-group investigation and its planned outcome measure, but does not provide the numerical outcome evidence needed to assess change. It neither supports a claim that the intervention did or did not improve symptoms nor permits a precise estimate of an effect.

13. Why This Trial Matters Statistically

This study is statistically notable because it makes the distinction between measuring change and estimating a treatment effect especially clear. MADRS was scheduled repeatedly in a single group, so the design could describe the participants’ symptom scores over the intervention period if those values were reported. A description of change is not the same as a comparison that attributes change to treatment.

The enrollment of 9 and pilot designation also highlight the role of precision. General statistical context: small studies often yield estimates that are sensitive to the observations included, and uncertainty can be substantial. Without the means, standard deviations, or uncertainty estimates, readers cannot tell whether any observed pattern was stable or imprecise. The record’s lack of numerical outcome results prevents even a descriptive assessment of the measured course.

The study also raises questions central to transparent analysis: which timepoint was primary, how repeated observations were handled, what the two listed analyses represented, and how missing measurements were addressed. Those details are not reported in the registry record. Clear reporting of estimands, analysis populations, missing-data methods, and all planned comparisons is important in any study, and especially useful when the sample is small and the design has no concurrent comparator.

The sample-size planning assumptions are also distinct from the registered design. The stated planning framework assumes equal allocation between two arms, whereas the study is recorded as single-group. This contrast is a reminder that a planning illustration is not a description of what participants experienced and is not evidence of observed power. In statistical interpretation, matching the design, estimand, and analysis assumptions is essential.

Overall, the record offers a useful case for reading a pilot study cautiously: identify the actual design, separate within-group change from causal comparison, and require estimates and uncertainty before drawing conclusions about an outcome.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main trial-specific limitation is the single-group design. The record lists no control group, with allocation recorded as NA and masking as NONE. Without a concurrent comparator, a change in MADRS during follow-up could not be distinguished from other influences on symptom scores. The design therefore limits causal interpretation even if numerical changes were available.

Enrollment was 9, and the study is described as a pilot. With this small number of participants, estimates may be imprecise and particularly sensitive to individual observations. However, numerical outcome estimates and their uncertainty are not reported in the registry record, so the actual precision cannot be assessed.

The registry record gives the primary outcome measure and its timepoints, but does not report the endpoint values, the number measured at each timepoint, or the analysis population. It also does not describe missing-data handling, the statistical model, or the meaning of the two listed analyses. These gaps prevent evaluation of the analysis and its reproducibility.

Further details about the enrolled population, antidepressant regimens, eligibility criteria, adherence, and concomitant care are not reported in the registry record. These details would help readers judge how consistently the intervention was used and to whom the study findings might apply. The record’s description of persistent depression despite adequate antidepressant doses provides context, but does not supply the full operational definitions used to select participants.

Finally, fatigue appears in the stated study purpose, but the primary endpoint information identifies MADRS, and a numerical fatigue outcome is not reported in the registry record. Safety reporting includes counts, but not event descriptions or attribution details. Together, these limitations mean that the record offers a concise description of the study design without enough outcome and methods information for a full assessment of efficacy, precision, or safety.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Effects of Testosterone in Women With Depression — NCT00676676.
• Registry record last updated 2012-11-30; status last verified 2012-11.
• Results first posted 2012-11-30.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT00676676 is a completed pilot study titled “Effects of Testosterone in Women With Depression.” Massachusetts General Hospital is listed as sponsor. The study began in 2007-03, had primary completion in 2008-10, and enrolled 9 participants.

The single-group study evaluated a testosterone patch delivering 300mcg daily for 8-weeks, added to current antidepressant therapy. The primary outcome was MADRS, summarized as a mean with standard deviation at baseline, 2-week, and 8-week. The study was not masked, and no comparator group is described.

The registry record does not report numerical MADRS results, the specific methods for the two listed analyses, the analysis population, or missing-data handling. It records 0 serious adverse events among 9 at risk and 2 participants affected by other adverse events among 9 at risk. The available information describes the study framework, but not enough outcome detail to evaluate the magnitude or precision of symptom change.